Pharmacological proteasome inhibitors and their therapeutic potential

被引：29

作者：

Dou, QP ^{[1
]}

Nam, S ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2000年 / 10卷 / 08期

关键词：

Alzheimer's disease; autoimmune disease; bone disease; cancer; inflammation; muscle wasting disease; neurological disease; Parkinson's disease;

D O I：

10.1517/13543776.10.8.1263

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Implication of the proreasome in human cancer, inflammation, autoimmune and other diseases has prompted design, synthesis and evaluation of various pharmacological proteasome inhibitors. In this review, we will summarise the literature related to human cancer cell death induction by proteasome inhibitors, examine the proteasome inhibitor patents published over the past five years and evaluate the potential clinical applications in the use of proteasome inhibitors for treating cancer and other human diseases.

引用

页码：1263 / 1272

页数：10

共 67 条

[11] The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis [J].

Delic, J ;

Masdehors, P ;

Ömura, S ;

Cosset, JM ;

Dumont, J ;

Binet, JL ;

Magdelénat, H .

BRITISH JOURNAL OF CANCER, 1998, 77 (07) :1103-1107

[12]

Dick LR, 1997, J BIOL CHEM, V272, P182

[13] Mechanistic studies on the inactivation of the proteasome by lactacystin A central role for clasto-lactacystin beta-lactone [J].

Dick, LR ;

Cruikshank, AA ;

Grenier, L ;

Melandri, FD ;

Nunes, SL ;

Stein, RL .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (13) :7273-7276

[14]

Dou QP, 1999, J PHARMACOL EXP THER, V289, P781

[15] Proteasome inhibitors as potential novel anticancer agents [J].

Dou, QP ;

Li, BY .

DRUG RESISTANCE UPDATES, 1999, 2 (04) :215-223

[16] Constitutive degradation of PML/RARα through the proteasome pathway mediates retinoic acid resistance [J].

Fanelli, M ;

Minucci, S ;

Gelmetti, V ;

Nervi, C ;

Gambacorti-Passerini, C ;

Pelicci, PG .

BLOOD, 1999, 93 (05) :1477-1481

[17] A BETA-LACTONE RELATED TO LACTACYSTIN INDUCES NEURITE OUTGROWTH IN A NEUROBLASTOMA CELL-LINE AND INHIBITS CELL-CYCLE PROGRESSION IN AN OSTEOSARCOMA CELL-LINE [J].

FENTEANY, G ;

STANDAERT, RF ;

REICHARD, GA ;

COREY, EJ ;

SCHREIBER, SL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (08) :3358-3362

[18] INHIBITION OF PROTEASOME ACTIVITIES AND SUBUNIT-SPECIFIC AMINO-TERMINAL THREONINE MODIFICATION BY LACTACYSTIN [J].

FENTEANY, G ;

STANDAERT, RF ;

LANE, WS ;

CHOI, S ;

COREY, EJ ;

SCHREIBER, SL .

SCIENCE, 1995, 268 (5211) :726-731

[19] The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome [J].

FigueiredoPereira, ME ;

Chen, WE ;

Li, JR ;

Johdo, O .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (28) :16455-16459

[20] Enhancement of CPP32-like activity in the TNF-treated U937 cells by the proteasome inhibitors [J].

Fujita, E ;

Mukasa, T ;

Tsukahara, T ;

Arahata, K ;

Omura, S ;

Momoi, T .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 224 (01) :74-79

← 1 2 3 4 5 6 7 →